Amgen wins patent block on Sanofi drug rival
15 July 2019 | By Victoria Rees (European Pharmaceutical Review)
Amgen has successfully blocked the manufacture, sales and marketing of its Sanofi drug rival in Germany.
List view / Grid view
Drug Markets
FDA grants Orphan Drug Designation to Imfinzi for SCLC
15 July 2019 | By Victoria Rees (European Pharmaceutical Review)
The FDA has announced Orphan Drug Designation for Imfinzi (durvalumab) to treat small cell lung cancer in combination with other therapies.
Controlled release drug delivery market to rise 14.3 percent
14 July 2019 | By Victoria Rees (European Pharmaceutical Review)
The global controlled release drug delivery market will be worth an estimated $91.2 billion by 2026, according to a new study.
Top five generic drug makers
12 July 2019 | By Victoria Rees (European Pharmaceutical Review)
The global generic drugs market continues to grow. With increasing demand for more accessible medication, pharmaceutical companies are harnessing the benefits offered by generic drugs. Here are the top five generic drugs makers by revenue.
US and EU enter Mutual Recognition Agreement for drug manufacturing inspections
12 July 2019 | By Victoria Rees (European Pharmaceutical Review)
The FDA and EMA have agreed to rely on each other’s assessment of pharmaceutical manufacturing sites to reduce duplicative work.
Judge overrules Trump effort to advertise drug prices
11 July 2019 | By Victoria Rees (European Pharmaceutical Review)
A federal judge in the US has said that the Trump administration cannot require pharmaceutical companies to include drug prices in advertisements as it is beyond their authority.
Chinese drug packaging industry set to be worth RMB200 billion
10 July 2019 | By Victoria Rees (European Pharmaceutical Review)
Pharmaceutical packaging in China has increased at a rate of 10 percent in recent years and is predicted to continue high growth.
NHS releases guidance to remove drugs from prescription list
9 July 2019 | By Victoria Rees (European Pharmaceutical Review)
Seven medications have been suggested for removal from prescriptions by the NHS after a public consultation.
Gastrointestinal drugs market set to reach $61.6 billion by 2024
9 July 2019 | By European Pharmaceutical Review
The rise of diseases such as inflammatory bowel syndrome is projected to drive the global gastrointestinal drugs market in the upcoming years.
EU releases guidance for medicine shortages
8 July 2019 | By Victoria Rees (European Pharmaceutical Review)
The EU has issued two guidance documents intended to advise the pharmaceutical industry and patients during medicinal shortages.
NICE endorses dacomitinib for treatment of lung cancer
8 July 2019 | By European Pharmaceutical Review
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.
US government takes steps to reduce drug costs
8 July 2019 | By Victoria Rees (European Pharmaceutical Review)
New regulations and legislations are being formed in the US to combat healthcare costs, including drug prices.
£3 million for no-deal Brexit medication transport
8 July 2019 | By Victoria Rees (European Pharmaceutical Review)
The DHSC has announced their plans for pharmaceutical transportation in the case of a no-deal Brexit.
Decision by NICE for the use of osimertinib to be appealed
7 July 2019 | By European Pharmaceutical Review
A pharmaceutical company will appeal a decision by NICE to not recommend osimertinib for use within NHS England.
FDA approves treatment for refractory multiple myeloma
5 July 2019 | By Victoria Rees (European Pharmaceutical Review)
Accelerated approval has been granted to Xpovio to treat refractory multiple myeloma by the FDA.
Follow: